EUCTR2021-005178-25-BE进行中（未招募）1 期
A Phase 1/2a, observer-blind, randomized, controlled, two-stage, multi-country study to evaluate the safety, reactogenicity, and immune response of the trivalent vaccine against invasive nontyphoidal Salmonella (iNTS) and Typhoid Fever in healthy European and African adults - INTS-GMMA GVGH-002
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 155
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •- Participants, who, in the opinion of the Investigator, can and will comply with the requirements of the protocol.
- •- Written or witnessed/thumb printed informed consent obtained from the participant prior to performance of any study-specific procedure.
- •- Healthy participants as established by medical history, clinical examination, and laboratory assessment.
- •- Participant satisfying screening requirements.
- •- A male or female between and including 18 and 50 years of age at the time of the first study intervention administration.
- •- Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy, or post-menopause.
- •- Female participants of childbearing potential may be enrolled in the trial if the participant:
- •o Has practiced adequate contraception for 1 month prior to study intervention administration, and
- •o Has a negative pregnancy test on the day of study intervention administration, and
- •o Has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administration series.
- •- Blood sample for simultaneous follicle-stimulating hormone (FSH) and estradiol levels may be collected at the discretion of the Investigator to confirm non-reproductive potential according to local laboratory reference range.
- •- Genetic testing for HLA-B27 will be performed at Screening and only participants with a negative result will be allowed to participate in the study*.
- •*Only for Stage 1.
- •- For Malawi (Stage 2), the participant lives in Blantyre and has agreed to remain in Blantyre for the study duration.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 155
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Medical Conditions
- •- Known exposure to S. Typhi and nontyphoidal Salmonella confirmed by blood culture during the period starting 3 years prior to first study intervention administration confirmed using past medical history.
- •- History of any reaction or hypersensitivity associated with any component of the study interventions.
- •- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- •- Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination or laboratory screening tests.
- •- Recurrent history or uncontrolled neurological disorders or seizures.
- •- Any clinically significant* hematological and/or biochemical laboratory abnormality.
- •* The Investigator should use his/her clinical judgment to decide which abnormalities are clinically significant from the panel of tests in the list of safety assays.
- •- Clinical conditions representing a contraindication to IM injections and/or blood draws.
- •- Any behavioral or cognitive impairment or psychiatric disease that in the opinion of the Investigator, may interfere with the participant’s ability to participate in the study.
- •- Confirmed positive COVID-19 polymerase chain reaction or lateral flow test during the period starting 28 days before the first administration of study vaccines (Day -28 to Day 1).
- •- Acute or chronic illness which may be severe enough to preclude participation.
- •- Any other clinical condition that, in the opinion of the Investigator, might pose additional risk to the participant due to participation in the study.
- •- All medical conditions will be assessed by the Investigator who may use his/her discretion to decide if the participant meets the exclusion criteria.
- •Prior/Concomitant Therapy
- •- History of receiving any typhoid vaccine (Ty21a, Vi capsular polysaccharide, or TCV) in the participant’s life.
- •- History of receiving any investigational iNTS or GMMA vaccines in the participant’s life.
- •- Use of any investigational or non-registered product other than the study interventions during the period beginning 30 days (Days -30 to 1) before the first dose of study interventions, or their planned use during the study period.
- •- A vaccine not foreseen by the study protocol administered during the period starting at 14 days before the first dose and ending 28 days after the last dose of study interventions administration*, with the exception of flu vaccines or COVID-19 vaccine.
- •*In case emergency mass vaccination for an unforeseen public health threat (eg, a pandemic) is recommended and/or organized by public health authorities outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine, provided it is used according to the local governmental recommendations and that the Sponsor is notified accordingly.
- •When regulations allow, the recommended time intervals for administration of these vaccines are at least 7 days before or 7 days after (at least 14 days before or 14 days after in case of live vaccines) each dose of study intervention administration.
- •- Administration of long-acting immune-modifying drugs at any time during the study period (eg, infliximab).
- •- Administration of Ig and/or any blood products or plasma derivatives during the period starting 3 months before the administration of the first dose of study interventions or planned administration during the study period.
研究者
相似试验
招募中
2 期
A study to evaluate safety, reactogenicity, and immune response of GSK Vaccines Institute for Global Health invasive nontyphoidal Salmonella (iNTS) TCV vaccine against invasive nontyphoidal Salmonella and Typhoid FeverPACTR202306838192573GlaxoSmithKline Biologicals SA155
进行中（未招募）
不适用
A phase I/II, observer-blind, randomized, controlled study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy male subjects aged 10-18 years. - HPV-011In female subjects from 10 years of age onwards for the prevention of cervical cancer by protecting against incident and persistent infections, cytological abnormalities including ASC-US, cervical intraepithelial neoplasia (CIN) and pre-cancerous lesions caused by oncogenic human papillomaviruses (HPV). In male subjects from 10 years of age onwards for the prevention of transmission of human papillomaviruses (HPV) causing persistent infections and related clinical outcomes.EUCTR2005-005943-24-FIGlaxoSmithKline Biologicals270
进行中（未招募）
1 期
Respiratory syncytial virus (RSV) investigational vaccine in infants aged 6 and 7 months likely to be unexposed to RSVEUCTR2018-000431-27-PLGlaxoSmithKline Biologicals176
进行中（未招募）
1 期
A study to evaluate safety and immunogenicity of GSK Biologicals' RSV investigational vaccine in RSV-seropositive infants aged 12 to 23 months.Active immunization of infants for the prevention of any lower respiratory tract infections (LRTIbronchiolitis and [broncho]pneumonia) associated with respiratory syncytial virus (RSV [subtypes A and B])MedDRA version: 21.1Level: LLTClassification code 10035692Term: Pneumonia due to respiratory syncytial virusSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 21.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 21.1Level: PTClassification code 10038718Term: Respiratory syncytial virus bronchiolitisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-000117-76-ITGLAXOSMITHKLINE BIOLOGICALS96
进行中（未招募）
1 期
Respiratory syncytial virus (RSV) investigational vaccine in infants aged 6 and 7 months likely to be unexposed to RSVActive immunization of infants for the prevention of any lower respiratory tract infections (LRTIbronchiolitis and [broncho] pneumonia) associated with respiratory syncytial virus (RSV).EUCTR2018-000431-27-GBGlaxoSmithKline Biologicals176